Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide‐induced acute lung injury

Abstract

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?

“…Reduction of cells apoptosis. [ 68 ] Portulaca oleracea hydroethanolic extract LPS-induced rat lung injury In vivo Portulaca oleracea hydroethanolic extract was used in the pretreatment of rats at 100 and 200 mg/kg. 1 h after, LPS at 50 mg/kg was intraperitoneally administered to induce lung injury.…”

“…Similar, in vivo investigations regarding LPS-induced lung injury have been performed for Physalis alkekengi L. var. franchetii [ 68 ], Portulaca oleracea hydroethanolic extract [ 69 ], Lianqinjiedu decoction [ 70 ], Aster tataricus extract [ 71 ], Cordyceps sinensis extract [ 72 ] and Ulmus davidiana extract [ 74 ]. Such studies were performed to investigate the effect of these complexes (with not reported active ingredients by these authors).…”

“…Overall, although no specific active compound was reported, the studies demonstrated that several types of administration and dosage regimens resulted in inhibition of inflammatory cytokines release, such as IL-β, IL-6, TNF-α, PGE2, and TGF-β, increase of white blood cells counts and improvement in histological examinations [ [68] , [69] , [70] , [71] , [72] , 74 ]. These in vivo results in animals are promising, considering the potential of these compounds to be further studied for the early treatment of stage 1 and stage 2 COVID-19 patients.…”

Tanreqing Inhibits LPS-Induced Acute Lung Injury In Vivo and In Vitro Through Downregulating STING Signaling Pathway

“…The pharmacological experiments have shown that TRQ has excellent antibacterial in vitro and anti-inflammatory activities in mucus hypersecretion models ( Wang et al, 2011 ; Liu et al, 2020 ). Clinical studies have revealed that TRQ shows therapeutic effects in respiratory diseases such as pneumonia, acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) ( Yang Y. et al, 2020 ). More importantly, TRQ has been recommended by numerous guidelines and expert consensus for the treatment of severe and critically ill patients with COVID-19 ( Zhuang et al, 2020 ).…”

Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice via Inhibiting TLR4/JNK/ERK/NF-κB Pathway

“…ALI, as a basic pathophysiological change of ARDS, is a challenging disease in the clinical setting [ 2 ]. It is characterized by the damage of the alveolar capillary system, increased pulmonary vascular permeability, diffuse alveolar injury, intra-alveolar fibrin, interstitial edema, and inflammatory cell infiltration [ 3 ]. Although ALI/ARDS has been studied in recent years, there is still a lack of effective ways to reduce its high mortality.…”